biology medicine news product technology definition

Credit Suisse raised their price target on shares of Facebook (NASDAQ: FB) to $31.00 in a research note issued on Tuesday. The firm currently has a “neutral” rating on the stock.

FB has been the subject of a number of other recent research reports. Analysts at Deutsche Bank reiterated a “buy” rating on shares of Facebook in a research note to investors on Tuesday. They now have a $40.00 price target on the stock. Separately, analysts at Bank of America reiterated a “buy” rating on shares of Facebook in a research note to investors on Monday. They now have a $35.00 price target on the stock. Finally, analysts at JPMorgan Chase reiterated an “overweight” rating on shares of Facebook in a research note to investors on Monday. They now have a $35.00 price target on the stock.

Twenty-four analysts have rated the stock with a buy rating, two have assigned an overweight rating, thirteen have issued a hold rating, and one has given a sell rating to the company’s stock. The stock presently has a consensus rating of “overweight” and a consensus target price of $32.42.

Shares of Facebook traded down 3.48% during mid-day trading on Tuesday, hitting $31.34. Facebook has a one year low of $17.55 and a one year high of $45.00. The stock’s 50-day moving average is currently $28.78. The company has a market cap of $67.896 billion and a P/E ratio of 168.23.

Facebook, Inc. (Facebook) is engaged in building products to create utility for users, developers, and advertisers.

By: DocMemory
Copyright © 2013 CST, Inc. All Rights Reserved